Future imaging-pathological correlation studies on postmortem material from patients scanned while alive continue to be key to further assess the utility of each of these three tracers to accurately quantify regional burdens of tau pathology in AD and to assess response to therapeutic interventions aimed at decreasing or stopping the progression of tau aggregation in AD. Here, MAPT is linked to Alzheimer disease.